⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
FDA Aging Regulatory Science Agenda
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-02 — FDA Leaders Name Longevity a Priority at ARDD: 2026 — ARDD Boston press coverage: FDA senior officials publicly named longevity a priority and said aging will be added to the agency’s regulatory science agenda, with discussion of how longevity therapies could be regulated; conference statements only, no draft guidance or rulemaking released. [expert-opinion] (novelty: 4)
Open questions
Related
Contributing findings
FDA Leaders Name Longevity a Priority at ARDD
02-oct-2026
novelty 4
per-area 4
strengthens